Focused On-demand Library for BRCA1-associated ATM activator 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6PJG6

UPID:

BRAT1_HUMAN

Alternative names:

BRCA1-associated protein required for ATM activation protein 1

Alternative UPACC:

Q6PJG6; A4D200; C9JY24; Q8IW85; Q8IZ43; Q8WVR8; Q96IV9; Q9H7J8; Q9UFA3

Background:

BRCA1-associated ATM activator 1, alternatively known as BRCA1-associated protein required for ATM activation protein 1, plays a pivotal role in the DNA damage response. It activates key kinases such as ATM, SMC1A, and PRKDC following ionizing radiation stress, modulating their phosphorylation status. Additionally, it is essential for mitochondrial function, cell proliferation, protein stability of MTOR and related proteins, and cell cycle progression influenced by growth factors.

Therapeutic significance:

BRCA1-associated ATM activator 1 is linked to severe diseases, including Rigidity and multifocal seizure syndrome, lethal neonatal, and Neurodevelopmental disorder with cerebellar atrophy, with or without seizures. Understanding its role could lead to groundbreaking therapeutic strategies for these debilitating conditions.